RBL1 and nonpapillary renal cell carcinoma: In the proliferation assays, we examined effect of RBL1 overexpression at different doses and found that only resistance to Sunitnib and Cabozantinib was observed whilst proliferation was not altered in ccRCC cell treated with Axitinib or Sorafenib (Additional file 1: Figure S1).